Skip to main content
. 2017 Sep 1;96(35):e7884. doi: 10.1097/MD.0000000000007884

Figure 2.

Figure 2

(A) Kaplan–Meier curves for progression-free survival and (B) overall survival (OS) rates for patients who received nab-paclitaxel (nab-PTX) alone and those who received carboplatin plus nab-PTX (CBDCA + nab-PTX) for relapsed small cell lung cancer.